# Updated long-term survival outcomes for patients with locally advanced gastric cancer having pathological complete response after neoadjuvant therapy at China National Cancer Center, 2004–2023

## TL;DR

Patients with advanced stomach cancer who achieved a complete response after pre-surgery treatment had good long-term survival, with no added benefit from further therapy.

## Contribution

Long-term survival data and factors influencing outcomes for gastric cancer patients achieving pCR after neoadjuvant therapy.

## Key findings

- 3- and 5-year OS rates were 90.2% and 83.3%, respectively, for pCR patients.
- Neoadjuvant chemotherapy improved OS and DFS in multivariate analysis.
- Combining immunotherapy with chemotherapy significantly increased the pCR rate.

## Abstract

Neoadjuvant chemotherapy increases the probability of achieving negative margins and may even lead to pathological complete response (pCR) in locally advanced gastric cancer (LAGC). The incorporation of neoadjuvant immunotherapy is promising in further enhancing the pCR rate. However, long-term survival outcomes and factors affecting the prognosis of pCR patients have not been fully elucidated.

We conducted a retrospective analysis of all patients who achieved pCR between January 2004 and June 2023. Cox regression models were used to identify clinicopathological predictors of overall survival (OS) and disease-free survival (DFS). Survival curves were plotted using the Kaplan–Meier method and compared using the log-rank test.

After screening, 112 patients were included in the study, with a median follow-up time of 42 (range: 2-117) months and a pCR rate of 7.4%. The 3- and 5-year OS rates were 90.2% and 83.3%, respectively, while the 3- and 5-year DFS rates were 86.8% and 82.0%, respectively. Within the multivariate Cox model, neoadjuvant chemotherapy was a prognostic factor for improved OS and DFS. There was no statistically significant disparity in OS and DFS between patients who received postoperative adjuvant therapy and those who did not. Moreover, the combination of neoadjuvant immunotherapy with chemotherapy, as compared to neoadjuvant chemotherapy alone, substantially increased the pCR rate (p <0.001).

Patients with LAGC who achieved pCR demonstrated favorable long-term survival outcomes, with no additional survival benefits conferred by adjuvant therapy. Although neoadjuvant immunotherapy increased the pCR rate, its impact on the prognosis of pCR patients requires further investigation.